Furthermore, a retrospective study of 282 ICI-treated KRAS-mutant advanced NSCLC patients revealed significantly better ICI efficacy in patients with higher PD-L1, pointing out PD-L1 expression as a prognostic factor for ICI response in KRAS-mutant tumors [66]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.